Ian L. Scott, Ph.D. 22906 111th St SE 0.348.7712 Monroe, WA 98272 EDUCATION * * * * 9 Ph.D.

Synthetic Chemistry, University of Sheffield, England, 1989 M.Phil. Synthetic Chemistry, University of Sheffield, England, 1986 B.Sc. (Honors) Chemistry, University of Sheffield, England, 1985 Postdoctoral Fellow under Dr. Marie Krafft, Florida State University, 1998-199 www.ianscottmolecular.com 36 email: is1143cb0@westpost.net

INDICATION AREAS OF EXPERIENCE Inflammation Congestive Heart Failure Psoriasis Parkinson's Disease Schizophrenia Cancer Diabetes Hypertension Cocaine Abuse Neuropathic Pain Alzheimer's Disease Rheumatoid Arthritis Age-Related Macular Degeneration Diabetic Retinopathy Dry-Eye Glaucoma

DRUG TARGETS Kinases (P38, MAPKAP2, MK-2) Growth Factors (FGF, VEGF) Integrin VLA-4/alpha4beta1 Endothelin A E-Selectin NMDA HDAC PTP-1B GABA beta-Secretase Dopamine D2 Serotonin Retinoid Isomerization RPE65

EXECUTIVE OVERVIEW

My scientific and leadership experience stems from 18 years of intense, fast-pac ed direction of research and development teams with Acucela Inc., AMRI, and Texa s Biotechnology Corporation. I bring creativity and rigorous scientific discipl ine to the invention of new medicines and have a proven track record of success: * * * * 5 clinical candidates 19 issued US patents & 12 patent families in prosecution 34 publications and presentations 6 invited speaking engagements

From R&D to operations, I provide a wide range of scientific knowledge, cross-fu nctional leadership, and management expertise to every aspect of drug discovery. My work includes the achievement of ambitious corporate and scientific goals wi th teams numbering from a just a few scientists, to as many as 60 staff distribu ted among global research sites. My specialty is the integration of all aspects of drug discovery, from early-sta ge research in chemistry and biology, through patent protection, pre-clinical d evelopment, IND-filing and support of Phase 1 and 2 clinical trials. I bring t he knowledge that only hands-on experience can generate to the design, synthesis and development of new, small-molecule pharmaceuticals. Hands-On Drug Discovery Experience * The establishment and management of successful research programs from leads g enerated by: * High throughput screening of synthetic compounds and natural products * Peptide mimetics of protein-protein interactions * Native ligands * Molecular modeling (de novo and rational drug design) * Management of in vitro and in vivo pharmacology research and development teams * Development of intellectual property strategies and authorship of patent appli cations * Establishment of commercially viable process chemistry routes to APIs * Management of CMC activities for API and drug product manufacture; stability t esting from candidate selection through IND filing to preparation for Phase 3 cl inical trials * Authorship of Section 7 * Management of toxicology programs in support of Phase1 and 2 clinical trials i ncluding 3, 6 and 9 month toxicology studies in several species; reproductive an d developmental toxicity studies and translational toxicity studies * Management of ADME programs in support of Phase 2 trials including identificat ion, structural determination, and bioanalytical method development for all huma n-relevant metabolites PROFESSIONAL EXPERIENCE Acucela Inc. Senior Director, Chemistry & Biology 2008 - 2010 Acucela Inc. Senior Director, Chemistry 2008 Acucela Inc. Director, Chemistry 2005 - 2008 AMRI Group (Executive) Director, Lead Discovery

2003 - 2005 AMRI Head of Operations: Bothell Research Center, Bothell, WA The Biosciences Group, Chicago, IL

2003 - 2005

AMRI Creator, The Oncology Group, Cross-divisional 2 - 2005 AMRI Assistant Director, Medicinal Chemistry 2002 - 2003 AMRI Section Head, Medicinal Chemistry 1999 - 2002 UT Medical School Adj. Asst. Professor (joint appt. with TBC)

200

1998 - 1999

Texas Biotechnology Corp. Texas Biotechnology Corp. Texas Biotechnology Corp.

Assistant Director 1998 - 1999 Principal Scientist 1996 - 1998 Senior Scientist 1992 - 1996

ACUCELA INC Bothell, WA Visual Cycle Modulation, AMD, Dry-Eye, Glaucoma Acucela is a biotechnology company focused on the discovery of new, small-molecu le therapeutics for the treatment of blinding eye diseases. Acucela's programs include: the Visual Cycle Modulator program for the treatment of Age-Related Mac ular Degeneration (AMD), which was out-licensed to Otsuka Pharmaceutical Company , Japan; and two in-licensed programs for the treatment of dry eye and glaucoma. I began my career at Acucela as the Director of Chemistry in 2005, shortly after Acucela in-licensed retinyl amide (ACU-3223) from the University of Washington for the treatment of AMD. In 2006, I assumed responsibility for the Next Gener ation Visual Cycle Modulator Program with the goal of identifying a non-retinoid modulator of the visual cycle (inhibitor of the isomerase enzyme RPE65). This program led to the invention of ACU-4429; currently in Phase 2 clinical trials f or the treatment of AMD. In 2008, I was promoted to Senior Director of Chemistr y and Biology, and assumed responsibility for all non-clinical research and deve lopment. My additional executive roles included Acting Head of Toxicology and ADME, and H ead of Intellectual Property. I was a member of the Joint Development Committee for collaboration with Otsuka Pharmaceuticals, and in 2009, received The Dr. Ku bota Award for outstanding achievement. The Visual Cycle Modulator Program ACU-4429 Research Program Leader: The Visual Cycle Modulator (VCM) program incl uded both ACU-3223 and ACU-4429. ACU-3223 was an internal program, in-licensed from the University of Washington. It led to the invention and development of A CU-4429, a novel, small-molecule inhibitor of RPE65 isomerase for the treatment of Age-Related Macular Degeneration (AMD). Accomplishments * Principle inventor of ACU-4429, currently in Phase II trials for AMD * Delivery of clinical candidate in less than 9 months (1 month ahead of schedul e) * Discovery of 6 novel, related chemical classes * Authorship of 6 patent applications * Leadership of the working groups with Otsuka in areas of research, CMC, toxico logy and non-clinical pharmacology * Creation of the overall research plan including initial SAR, back-up program,

IP, MOA studies, and the generation of new animal models for ocular disease * Chemistry team leader (5 internal, 6 external chemists) * Biology team leader (9 biologists including the vivarium) * Initiated, managed and completed studies including: 3, 6 and 9-month toxicolog y, pilot development and pilot fertility * Managed the metabolite identification program - Identified major human metabo lites * Managed the CRO responsible for development and validation of bioanalytical me thods for parent and metabolites * Designed and implemented translational toxicology studies * Managed CMC including API and drug product manufacture, and submission of CMC Section 7 * Established and implemented patent protection strategies * Managed chemistry outsourcing to India ACU-3223 Program ACU-3223 was Acucela's first clinical candidate and completed Phase I trials for the treatment of Age-Related Macular Degeneration. My work involved the creati on of a viable large-scale synthetic route to an oxygen, heat and light sensitiv e molecule; management of CROs responsible for API and drug product manufacture; authorship of the CMC Section 7. AMRI Bothell, WA - Chicago, IL - Albany, NY Albany Molecular Research is one of the largest chemistry CROs for the pharmaceu tical industry. AMRI focuses on medicinal and process chemistry research, large -scale manufacturing, natural product libraries and enzyme bio-catalysis. My career at AMRI began in the Medicinal Chemistry Group as Section Head (1999). I was responsible for projects in many therapeutic areas and became Team Lead er for all contracted projects with two global pharmaceutical companies. A larg e part of my research was focused on the treatment of neurological disorders inc luding several neurodegenerative diseases. In 2002, as Assistant Director of M edicinal Chemistry, I was responsible for ~30 chemists (mostly Ph.D.) divided be tween 6 external and 2 internal research teams. During my tenure in the Medici nal Chemistry Group, I established and ran The Oncology Group. My oversight of this group continued as my career progressed beyond medicinal chemistry and led to the identification of a clinical candidate. In 2003, I was promoted to Group Director, Discovery and relocated to Bothell, W A as Head of Operations of the Bothell Research Center. Later that year, my re sponsibilities increased to include The Biosciences Group, Chicago. AMRI: BOTHELL RESEARCH CENTER Bothell, WA Novel Antibiotics

Natural Products, High Throughput Screening,

The Bothell Research Center focuses on the use of natural products in drug disco very (33 staff members). My initial mandate as Head of Operations was to evalua te the ongoing research programs, teams and scientific approaches, and to implem ent changes to maximize the potential of the division. My responsibilities spa nned all departments including science, finance, facilities and business develop ment.

Accomplishments: * * * * Primary mandate accomplished in less than 2 years Restructured the organization to improve efficiency and product marketability Created separate structural analysis and microbiology teams Created a new high throughput screening group

* Instituted new protocols for the establishment of quality natural product libr aries * Increased the quality and quantity of the research with new methodology and te chnology * Designed and managed the build-out of a new facility / Refurbished the existin g building * Introduced a new billing paradigm now referred to as the flexi-FTE * Redesigned the business presentation to better market AMRI's technology * Co-invented a novel approach for the discovery of new antibiotics from natural products AMRI: THE BIOSCIENCES GROUP Chicago, IL Enzymes, Microbes, Organic Synthesis The Biosciences group in Chicago was focused on the use of enzymes and microbes for organic synthesis (28 staff members). My mandate as Head of this division c losely paralleled that for the Bothell Research Center. I evaluated the ongoing research programs, teams and scientific approaches, and implemented changes to maximize the potential of the division. Accomplishments: * Primary mandate accomplished in 1 year * Improved the quality of the science * Increased the customer base AMRI: THE ONCOLOGY GROUP Trans-divisional

Natural Products, Biocatalysis, Cancer Therapeutics

I established The Oncology Group as part of an initiative to create internal res earch programs. A major goal of my team was to leverage the company's strengths in natural products and bio-catalysis. Accomplishments: * Discovered a novel vinca derivative, ALB-109564(a); completed phase I clinical trials * Team leader responsible for all start-up activities of new group including set ting criteria for project selection and identifying suitable programs * Managed medicinal chemistry optimization of lead molecules * Author and principal inventor on 3 issued US patents MEDICINAL CHEMISTRY AMRI Albany, NY The medicinal chemistry group in Albany was primarily focused on external contra cts. Most of my contracts served global pharmaceutical companies. Details of t hese programs are still considered confidential. Roles / Accomplishments:

* Team leader for all projects for two global pharmaceutical companies * Team leader for projects with several smaller biotechnology companies * Team leader on 2 internal programs * * * * Periodic review of all programs within the medicinal chemistry department Mentored new project leaders Supervision of 30 chemists (on average), mostly Ph.D. Management of up to 8 teams simultaneously

* Design and management of build-out of two new chemistry laboratories * Named inventor on 8 issued US patents from external programs

TEXAS BIOTECHNOLOGY CORP. Houston, TX Peptide Mimetics, De Novo Design, Homology Ligand-Based Design Inflammatory and Cardiovascular Disease Texas Biotechnology was a small pharmaceutical company focused on the discovery of new treatments for inflammatory and cardiovascular diseases. Project Team Leader: VLA-4/VCAM Integrin * * * * Lead compound, TBC-4746, progressed through Phase II clinical trials Responsible for design of entry compound into a new series (peptide mimetic) Responsible for lead optimization Principal inventor on 4 issued US patents

Project Team Leader: FGF and VEGF Growth Factor Programs * Used De Novo Design to discover new class of inhibitors * Named inventor on 2 filed patent applications E-Selectin * Used homology modeling and ligand-based design strategies to discover several new classes of E-Selectin inhibitors * Developed process scale route to clinical candidate, TBC-1269 (Bimosiamose) * Improved "med chem" method (< 0.1% overall yield, 95% HPLC purity after prep H PLC) to API method (56% overall yield, 99.7% HPLC purity, no chromatography) * Program progressed to Phase II clinical trials * Named inventor on 3 issued US Patents UNIVERSITY OF TEXAS MEDICAL SCHOOL Adjunct Assistant Professor, Dept. of Internal Medicine (Joint appt. with Texas Biotechnology Corporation) AWARDS * Dr. Kubota Award, 2009 PROFESSIONAL MEMBERSHIPS * American Chemical Society * Royal Society of Chemistry: MRSC, CCHEM

GLOBAL PARTNERSHIPS I frequently travel internationally to maintain advantageous corporate and scien tific partnerships with pharmaceutical/biotechnology businesses overseas. I've recently traveled to both India and Japan for Acucela Inc. Partnerships: Otsuka Pharmaceuticals, Japan; Sai Adventium, Pune, India; Jubilant Chemsys, Noi da, India PUBLICATIONS * A Simple Strategy for the Preparation of 6-Substituted 3H-Benzoxazol-2-ones an d 3H-Benzothiazol-2-ones, Russell J. DeOrazio, Jun-Ho Maeng, David D. Manning, B rian A, Sherer, Ian L. Scott, Sham S. Nikam, Synth Commun, In Press. * Synthesis and SAR of Vinca Alkaloids, Voss, Matthew E.; Ralph, Jeffery M.; Xie , Dejian; Manning, David D.; Chen, Xinchao; Frank, Anthony J.; Leyhane, Andrew J .; Liu, Lei; Stevens, Jason M.; Budde, Cheryl; Surman, Matthew D.; Friedrich, Th omas; Peace, Denise; Scott, Ian L. Wolf, Mark; Johnson, Randall, Bioorg. and Med . Chem. Lett., 2009, 19, 1245-1249. * Protective Effects of Myricetin and Related Flavanols Against A2E and Light Me diated-Cell Death in Bovine Retinal Primary Cell Culture, Aicha Laabich, Corinne C. Manmoto, Vladimir Kuksa, David W. Leung, Ganesh P. Vissvesvaran, Ibrahim Kar liga, Mahesh Kamat, Ian L. Scott, Ahmad Fawzi and Ryo Kubota, Experimental Eye R esearch, 2007, 85, 154-165. * Selectin Blockade Prevents Antigen-induced Late Bronchial Responses and Airway Hyperresponsiveness in Allergic Sheep, William M. Abraham, Ashfaq Ahmed, Juan R . Sabater, Isabel T. Lauredo, Yelena Botvinnikova, Robert J. Bjercke, X. Hu, B. Mitch Revelle, Timothy P. Kogan, Ian L. Scott, Richard A. F. Dixon, Edward T. H. Yeh, and Pamela J. Beck, Am. J. Respir. Crit. Care Med., 1999, 159, 1205-1214. * Application of Glycomimetic Design in the Discovery of the Selectin Antagonist TBC1269: Kogan, Timothy P., Dupre, Brian, Bui, Helen, Keller, Karin M., McAbee, Kathy L., Kassir, Jamal M., Scott, Ian L., Market, Robert V. Vanderslice, Pete r, Beck, Pamela J., and Dixon, Richard A. F., Med. Chem. Res.,1998, 8, 370-382. * Dienes from the Thermolysis of Dicobalthexacarbonyl-Complexed Enynes: Mechanis tic Insight: Marie E. Krafft, Anne M. Wilson, Olivier A. Dasse, Llorente V. R. B onaga, Y. Y. Cheung, Zice Fu, Bin Shao and Ian L. Scott, Tetrahedron Lett., 1998 , 39, 5911-5914. * Stereospecific *-Mannosylation, Ian L. Scott, Robert V. Market, Russell J. DeO razio, Harold Meckler, and Timothy P. Kogan, J. Carbohydr., Res. 1999, 317, 210216. * Novel Synthetic Inhibitors of Selectin-Mediated Cell Adhesion: Synthesis of 1, 6-Bis[3-(3-carboxymethylphenyl)-4-(2-*-D-mannopyranosyloxy)phenyl]hexane (TBC126 9): Timothy P. Kogan, Brian Dupre, Huong Bui, Kathy L. McAbee, Ian L. Scott, Xin Hu, Peter Vanderslice, Pamela J. Beck, and Richard A. F. Dixon, J. Med. Chem., 1998, 41, 1099-1111. * Glycomimetic Selectin Inhibitors: (*-D-Mannopyranosyloxy)methyl-biphenyls: Bri an Dupre, Huong Bui, Ian L. Scott, Robert V. Market, Karin M. Keller, Pamela J. Beck and Timothy P. Kogan, Biorg. and Med. Chem. Letts., 1996, 6, 569-572. * Steric vs. Electronic Effects in the Pauson-Khand Reaction: Marie E. Krafft, R omulo H. Romero and Ian L. Scott, Synlett, 1995, 577-578. * Rational Design and Synthesis of Small Molecule, Non-oligosaccharide Selectin Inhibitors: (*-D-Mannopyranosyloxy)biphenyl-Substituted Carboxylic Acids: Timoth y P. Kogan, Brian Dupre, Karin M. Keller, Ian L. Scott, Huong Bui, Robert V Mark et, Pamela J. Beck, Jennifer A. Voytus, B. Mitch Revelle, and Delores Scott, J. Med. Chem., 1995, 38, 4976-4984. * Effect of Coordinating Ligands on the Pauson-Khand Cycloaddition: Trapping of an Intermediate, Marie E. Krafft, Ian L. Scott, Romulo H. Romero, Sabine Feibelm ann, Craig E. Van Pelt, J. Am. Chem. Soc. 1993, 115, 7199-7207. * The Chemistry of D-Glucurono-6,3-lactone Diethyl Dithioacetal: Synthesis of 4,

5-Dideoxy-aldehydo-L-erythro-hex-4-enono-6,3-lactone Diethyl Dithioacetal, D. Ne ville Jones, Ian L. Scott, William W. Wood, J. Chem. Res. (S), 1992, 270-271; (M ), 1992, 2137-2168. * Acceleration of the Thermal Pauson-Khand Reaction by Coordinating Ligands, Mar ie E. Krafft, Ian L. Scott, Romulo H. Romero, Tetrahedron Lett., 1992, 33, 38293832. * Pauson-Khand Reaction with Electron-Deficient Alkynes, Marie E. Krafft, Romulo H. Romero, Ian L. Scott, J. Org. Chem.1992,57, 5277-5728. * The Directed Pauson-Khand Reaction, Krafft, M.E.; Juliano, C.A.; Scott, I.L.; Wright, C.; McEachin, M.D. J. Am. Chem. Soc. 1991, 113, 1693-1703. * The Synthesis and Attempted Cyclization of Some *-Acyloxy Carbohydrate Epoxide s, Keith Jones, John McEvoy, William W. Wood, Ian L. Scott, J. Chem. Res. (S), 1 987, 213;(M), 1987, 1774-1790. PATENTS, U.S. Issued * "Vinca Derivatives" I. L. Scott, J. M. Ralph and M. E. Voss, US 7,745,619, Jun e 29, 2010 (WO 05/055939, June 23, 2005). * "Diaryl Substituted Pyridinones" B. Devadas; Walker, John,S. R. Selness, T. L. Boehm, R.C. Durley, R. Devraj, B. S. Hickory, P. V. Rucker, K. D. Jerome, H. M. Madsen, E. Alvira, M. A. Promo, R. M. Blevis-Bal, L. D. Marrufo, J. O. T. Hitch cock, W. Owen, T. Naing, L. Xing, H. S. Shieh, A. Sambandam, S. Liu, I. L. Scott , and K. F. McGee, US 7,629,363, December 8, 2009 (WO 05/018557, March 3, 2005) . * "Vinca Derivatives" I. L. Scott, J. M. Ralph and M. E. Voss, US 7,238,704, Jul y 3, 2007 (WO 05/055939, June 23, 2005). * "Vinorelbine Derivatives" I. L. Scott, J. M. Ralph and M. E. Voss, US 7,235,56 4, June 26, 2007 (WO 05/055943, June 23, 2005). * "Substituted pyridinones as modulators of p38 MAP kinase" B. Devadas; Walker, John,S. R. Selness, T. L. Boehm, R.C. Durley, R. Devraj, B. S. Hickory, P. V. Ru cker, K. D. Jerome, H. M. Madsen, E. Alvira, M. A. Promo, R. M. Blevis-Bal, L. D . Marrufo, J. O. T. Hitchcock, W. Naing, L. Xing, H. S. Shieh, A. Sambandam, S. Liu, I. L. Scott, and K. F. McGee, US 7,067,540, June 27, 2006 (WO 03/068230, Au gust 23, 2003). * "Cyclohexylamine Derivative As Subtype Selective NMDA Receptor Antagonists" R. J. DeOrazio, S. S. Nikam, I. L. Scott, B. A. Sherer and L. D. Wise, US 6,919,37 7, July 19, 2005 (WO 01/81295, November 1, 2001). * "Carboxylic Acid Derivatives that Inhibit the Binding of Integrins to Their Re ceptors" R. J. Biediger, Q. Chen, G. W. Holland, J. M. Kassir, W. Li, R. V. Mar ket, I. L. Scott and C. Wu, US 6,972,296, December 6, 2005 (WO 00/67746, Novembe r, 16, 2000). * "Cyclohexylamine Derivatives as Subtype Selective N-Methyl-D-Aspartate Antagon ists" S. S. Nikam, I. L. Scott, B. A. Sherer, L. D. Wise, US 6,828,341, Decembe r 7, 2004 (WO 01/92239, December 6, 2001). * "Bicyclic Cyclohexylamine Derivatives and Their Use as NMDA Receptor Antagonis ts" S. S. Nikam, I. L. Scott, B. A. Sherer, L. D. Wise, US 6,794,402, September 21, 2004. * "Bicyclic Cyclohexylamine Derivatives and Their Use as NMDA Receptor Antagonis ts" R. J. DeOrazio, S. S. Nikam, I. L. Scott, B. A. Sherer, L. D. Wise, US 6,68 3,101, January 27, 2004 (WO 01/94321, December 13, 2001). * "Cyclohexylamine Derivatives as Subtype Selective NMDA Receptor Antagonists" R. J. DeOrazio, S.S. Nikam, I. L. Scott, B. A. Sherer, L. D. Wise, UD 6,765,022, July 20, 2004 (WO 01/92204, December 6, 2001). * "Propanoic Acid Derivatives that Inhibit the Binding of Integrins to Their Rec eptors " R. J. Biediger, B. Dupre, L. K. Hamaker, G. W. Holland, J. M. Kassir, W . Li, R. V. Market, N. Nguyen, I. L. Scott, C. Wu, E. R. Decker, US 6,723,711, April 20, 2004 (WO 00/68188, November, 16, 2000). * "N,N-Disubstituted Amides that Inhibit the Binding of Integrins to their Recep tors" R. J. Biediger, V. O. Grabbe, G. W. Holland, J. M. Kassir, T. P. Kogan, S. Lin, R. V. Market, B. Raju, I. L. Scott, and C. Wu, US 6,194,448, February 27,

2001 (WO 99/52898, October 21, 1999). * "Piperidine Derivatives as Subtype Selective N-Methyl-D-Aspartate Antagonists" B. E. Kornberg, R. A. Lewthwaite, D. M. Manning, S. S. Nikam and I. L. Scott, U S 6,642,256, November 4, 2003 (WO 02/50070, June 27, 2002). * "Compounds that Inhibit the Binding of Integrins to Their Receptors" R. J. Bie diger, V. O. Grabbe, G. W. Holland, J. M. Kassir, K. M. Keller, T. P. Kogan, S. Lin, R. V. Market, B. Raju, I. L. Scott, and C. Wu, US 6,262,084, July 17, 2001. * "Compounds that Inhibit the Binding of Integrins to Their Receptors" I. L. Sco tt, , B. Raju, R. J. Biediger, V. O. Grabbe, J. M. Kassir, K. M. Keller, T. P. K ogan, S. Lin, R. V. Market , US 6,096,773, August 1, 2000 (WO 99/52493, October 21, 1999). * "Di- and Trivalent Small Molecule Selectin Inhibitors" T. P. Kogan, B. Dupre, I. L. Scott, H. Bui, K. L. Wheeler, K. M. Keller, and J. M. Kassir, US 5,919,76 8, December 22, 1998 (WO 97/01335, January 16, 1997). * "High Yield Stereospecific Mannosylation" I. L. Scott and T. P. Kogan, US 5,71 2,387, January 27, 1998 (WO 97/44344, November 27, 1997). * "Binding of E-Selectin or P-Selectin to Sialyl-Lewisx or Sialyl-Lewisa" T. P. Kogan, B. Dupre, I. Scott, K. Keller, H. Dao, and P. Beck, US 5,444,050, August 22, 1995 (WO 95/29682, November 9, 1995). PCT * "Preparation of Phenylpropylamine Derivatives for Treating Ophthalmic Diseases and Disorders" Scott, Ian L.; Kuksa, Vladimir A.; Kubota, R., WO 10/048332, Apr il 29, 2010. * Sulfur-Linked Compounds for Treating Ophthalmic Diseases and Disorders" Scott, Ian L.; Kuksa, Vladimir A.; Kubota, R., WO 10/028088, March 11, 2010. * "Amine Derivative Compounds for Treating Ophthalmic Diseases and Disorders" Sc ott, Ian L.; Kuksa, Vladimir A.; Orme, Mark W., Hong, Feng, Little, Thomas L., K ubota, R.; WO 09/058216, May 7, 2009. * "Alkoxy Compounds for Disease Treatment" Scott, Ian L.; Kuksa, Vladimir A.; Or me, Mark W.; Little, Thomas L.; Gall, Anna; Hong, Feng.; WO 09/045479, April 9, 2009. * "Alkynylphenyl Derivative Compounds for Treating Ophthalmic Diseases" Scott, I an Leslie; Kuksa, Vladimir Aleksandrovich; Orme, Mark W.; Little, Thomas; Gall, Anna; Gage, Jennifer; Hong, Feng, WO 09/005794, January 8, 2009. * "Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders" Scott, Ian Leslie; Kuksa, Vladimir Aleksandrovich; Gall, Anna; Orme, Mark W.; G age, Jennifer; Little, Thomas L., Jr.; Jiang, Qin; Rossiter, Lana Michele; McGee , Kevin F., Jr.; Kubota, Ryo, WO 08/131368, October 30, 2008. * "Preparation of Vinorelbine Derivatives as Antitumor Agents" M. W. Wolf, P. R. Guzzo and I. L. Scott, WO 08/033935, March 20, 2008. * "Preparation of Vinca Alkaloid Derivatives as Antitumor Agents" M. W. Wolf, P. R. Guzzo and I. L. Scott, WO 08/033930, March 20, 2008. * "Pharmaceutical Compositions Containing Retinylamine Derivatives for the Treat ment of ophthalmic Diseases and Disorders" R. Kubota, A. Fawzi and I. L. Scott, WO 07/089673, August 8, 2007. * "Compounds that Inhibit the Binding of Vascular Endothelial Growth Factor to its Receptor" I. L. Scott, R. J. Biediger, and R. V. Market, WO 98/53790, Decemb er 3, 1998. * "Polysulfolithocolic Acids as Growth Factor Receptor Inhibitors" T. P. Kogan, R. J. Biediger, C. C. Stephan, R. G. Tilton, I. L. Scott, T. A. Brock, WO 98/031 81, January 29, 1998. * "Method for Inhibiting the Binding of Selectins to Sialyl-Lewises" T. P. Kogan , I. L. Scott, K. M. Keller, B. Dupre, R. J. Bjercke, R. J. Market, S. J. Sherwo od, E. T. Yeh, R. G. Tilton, P. N, T, Kint, H. M. Bui and P. J. Beck, WO 96/3541 8, November 14, 1996.

INVITED PRESENTATIONS * "Visual Cycle Modulation as an Approach to the Treatment of Age-Related Macula r Degeneration" Neuron to Synapse, New York, June 2010. * "Visual Cycle Modulation: An Approach to the Treatment of Age-Related Macular Degeneration" Neuron to Synapse, Boston, May 2008. * "Multiple Roles for Selectins in Inflammation: Discovery and Development of TB C1269" NHLI: Conquering Airway Inflammation in the 21st Century, London, Septemb er, 1998. * "Bringing Adhesion to a Rolling Stop" The Society for Medicines Research: Ther apetic Aspects of Cell Adhesion", London, September 1998. * "Developing a Model of Selectin-Carbohydrate Interactions for Use in Drug Desi gn: Reality or Fantasy?" The Society of Chemical Industry: Understanding Protein /Protein Interactions, London, June 1998. * "Application of Glycomimetic Design in the Discovery of the Selectin Antagonis t TBC1269" The 26th National Medicinal Chemistry Symposium, Richmond, VA, June 1 998. PRESENTATIONS * "Age-Related Macular Degeneration, Disease and Progress Towards Treatment", Ia n Scott, Ryo Kubota, Claes Bavik, Neurodegenerative Diseases: New Molecular Mech anisms, Keystone Symposium, February 2009 (poster). * "Novel Therapy for Non-Exudative AMD" C. Bavik, K. Murata, T. McGinn, S. Zhong , S. Hayes, K. Lieu, I. Scott and R. Kubota, Reducing Disparities in Eye Disease and Treatment, ARVO 2009 Annual Meeting, May 2009 (poster). * "Synthesis and SAR of Novel 11'-Vinorelbine, 12'-Vinblastine, and 12'Vincristi ne Alkaloid Analogs" 236th ACS National Meeting, Philadelphia, PA, August, 2008. * "Pauson-Khand Reaction with Electron Deficient Alkynes" 204th American Chemic al Society National Meeting, Washington, DC, August 1992. * "The Synthetic Utility of D-Glucurono-6,3-lactone as a Starting Material" The Royal Society of Chemistry Carbohydrate Group Spring Meeting, 1988. * "Towards the Total Synthesis of Phomopsolides A and B" The Royal Society of Ch emistry Carbohydrate Group Spring Meeting, 1987. * "Stereospecific *-Mannosylation: Development of a Selectin Inhibitor" I. L. Sc ott and R. V. Market, Gordon Research Conference: Carbohydrates, July, 1997 (pos ter).